KEY DETAILS
A Phase 2 trial of tirzepatide and organ-specific biological aging, dated October 30, 2026, is enrolling by invitation.
A Phase 2 trial of the herbal formula Guominkang for diabetic kidney disease, dated October 30, 2026, is listed as active, not recruiting.
On October 30, 2026, HHS posted a notice of availability for a 503A peptide compounding enforcement discretion policy, with written comments accepted for two weeks after publication.
Phase 3 ATTAIN-J, published October 30, 2026, found oral orforglipron reduced bodyweight more than placebo in Japanese adults with obesity.
A Phase 3 trial published on October 30, 2026 in The Lancet Diabetes & Endocrinology found that once-daily oral orforglipron led to statistically superior bodyweight reductions compared with placebo in Japanese adults with obesity disease. On the same date, HHS posted a notice of availability for an enforcement discretion policy on 503A compounding using certain peptide bulk drug substances, with written comments accepted for two weeks after publication. This may be useful if you follow GLP-1 research and compounding policy.
This entry describes a study plan, not a finding. The sponsor is Atria Research and Global Health Institute (ARGHI), and the trial identifier is NCT07906041. The purpose is laid out plainly. The ClinicalTrials.gov registration says the study will evaluate blood-based measures of organ-specific biological age, with a particular focus on the brain, and investigate how those measures relate to established clinical indicators of health and how they respond to treatment with tirzepatide. The registration lists an estimated enrollment of 22 and reports no results.
This trial looks at a different kind of treatment. Beijing University of Chinese Medicine sponsors the study (NCT07907965) of Guominkang, which the trial registration calls a traditional Chinese herbal formula, in people with diabetic kidney disease. The background needs a careful read. The registration says that in earlier animal studies, Guominkang reduced urine protein and blood sugar in mice with diabetic kidney disease, and those are findings in mice, not in people. The study description says the pilot study will enroll 18 adults aged 18 to 70 with mild-to-moderate kidney damage, while the listed enrollment figure is 15. The registration lists a start date of October 20, 2025 and an estimated study completion date of October 27, 2026.
Here is where things stand on the policy side. HHS posted this document (identifier 2026-22192) in the Federal Register on October 30, 2026, and its status is a notice of availability. The wording matters here. The notice says it describes the HHS Secretary's enforcement policy on using certain peptide bulk drug substances in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, while the 503A bulks list is developed through rulemaking. The notice says written comments can be submitted through regulations.gov until two weeks after publication.
This is the study behind the headline. ATTAIN-J was a double-blind, randomised, placebo-controlled, parallel-group Phase 3 trial, published in The Lancet Diabetes & Endocrinology on October 30, 2026 (DOI 10.1016/S2213-8587(26)00232-9). The main result is clear. In Japanese adults with obesity disease, once-daily orforglipron led to statistically superior reductions in bodyweight compared with placebo, with a safety profile consistent with that of other GLP-1 receptor agonists.
That covers all four items. Each one has a full entry on glp1laws.com, with links to the original trial registrations, the Federal Register notice and the journal abstract, where you can read the original wording for every detail above. Those pages are the best place to check anything you want to confirm.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.